Correct spelling for the English word "LHICDH" is [lˈɪkd], [lˈɪkd], [l_ˈɪ_k_d] (IPA phonetic alphabet).
LHICDH is an abbreviation for L-2-hydroxyisocaproate dehydrogenase, an enzyme that plays a significant role in the metabolism of certain amino acids. The acronym LHICDH is derived from the enzyme's full molecular name.
L-2-hydroxyisocaproate dehydrogenase is a specific type of dehydrogenase enzyme that is involved in various biochemical reactions within the body. Dehydrogenases are responsible for catalyzing the oxidation or reduction of specific molecules by transferring hydride ions or hydrogen atoms, respectively. In the case of LHICDH, this enzyme catalyzes the reversible conversion of L-2-hydroxyisocaproate to 2-oxoisocaproate in the presence of nicotinamide adenine dinucleotide (NAD+).
LHICDH is primarily found in certain tissues, including the liver and kidneys, where it participates in the metabolism of branched-chain amino acids (BCAAs). BCAAs are a group of essential amino acids, namely leucine, isoleucine, and valine, that serve as building blocks for protein synthesis. The activity of LHICDH is crucial for the catabolism of BCAAs, facilitating their breakdown and conversion into intermediates that can further be utilized for energy production or other metabolic pathways.
Discrepancies or dysfunctions in LHICDH activity may lead to metabolic disorders or imbalances, such as branched-chain ketoaciduria. These conditions typically manifest with symptoms like neurological abnormalities, developmental delays, and metabolic acidosis. Further research and understanding of LHICDH can provide insights into these disorders and potentially contribute to the development of therapeutic interventions aimed at restoring metabolic homeostasis.